Human Insulin Market by Product (Drug and Drug Delivery Devices) for Type 1 Diabetes, Type 2 Diabetes Application - Global Industry Perspective, Comprehensive Analysis, Size, Share, Growth, Segment, Trends and Forecast, 2015 - 2021
- ZIO1027865
- 110 Pages
- August 2016
- Medical Devices
The report covers forecast and analysis for the human insulin market on a global and regional level. The study provides historic data of 2015 along with a forecast from 2016 to 2021 based on revenue (USD Billion). The study includes drivers and restraints for the human insulin market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the human insulin market on a global level.
This report offers comprehensive coverage on global human insulin market along with, market trends, drivers, and restraints of human insulin market. This report includes a detailed competitive scenario and product portfolio of key vendors. To understand the competitive landscape in the market, an analysis of Porter’s five forces model for the human insulin market has also been included. The study encompasses a market attractiveness analysis, wherein all segments are benchmarked based on their market size, growth rate, and general attractiveness. This report is prepared using data sourced from in-house databases, secondary and primary research team of industry experts.
The study provides a decisive view on the human insulin market by segmenting the market based on product, application, and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2015 to 2021. The product based market covered under this study includes drugs and drug delivery devices. The application segmentation includes insulin dependent diabetes mellitus and non-insulin dependent diabetes mellitus. The regional segmentation includes the current and forecast demand for North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa.
Key market players of human insulin market include Eli Lilly, GlaxoSmithCline, Biocon, Sanofi Aventis, Julphar, Novo Nordisk, SemBioSys, and Wockhardt.
This report segments the global human insulin market as follows:
Human Insulin Market: Product Segment Analysis
- Drugs
- Insulin Analogs and Biosimilars
- Human Insulin Biologics
- Drug Delivery Devices
- Pens
- Pen Needles
- Syringes
Human Insulin Market: Application Segment Analysis
- Insulin dependent diabetes mellitus (Type 1)
- Non-Insulin dependent diabetes mellitus (Type 2)
Human Insulin Market: Regional Segment Analysis
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
- Chapter 1. Introduction
- 1.1. Report Description And Scope
- 1.2. Research Scope
- 1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology
- Chapter 2. Executive Summary
- 2.1. Global Human Insulin Market, 2015 - 2021 (USD Billion)
- 2.2. Global Human Insulin Market: Snapshot
- Chapter 3. Human Insulin – Market Dynamics
- 3.1. Introduction
- 3.2. Value Chain Analysis
- 3.3. Market Drivers
- 3.3.1. Global Human Insulin Market Drivers: Impact Analysis
- 3.3.2. Rise in Diabetic Patient Population.
- 3.3.3. Increasing Population Exposure to Key Risk Factors Leading to Diabetes.
- 3.4. Market Restraints
- 3.4.1. Global Human Insulin Market Restraints: Impact Analysis
- 3.4.2. Stringent Regulatory Requirements for Product Approval.
- 3.5. Opportunities
- 3.5.1. Emerging Markets
- 3.6. Porter’s Five Forces Analysis
- 3.6.1. Bargaining Power Of Suppliers
- 3.6.2. Bargaining Power Of Buyers
- 3.6.3. Threat From New Entrants
- 3.6.4. Threat From New Substitutes
- 3.6.5. Degree Of Competition
- 3.7. Market Attractiveness Analysis
- 3.7.1. Market Attractiveness Analysis, By Type Segment
- 3.7.2. Market Attractiveness Analysis, By Application Segment
- 3.7.3. Market Attractiveness Analysis, By Regional Segment
- Chapter 4. Global Human Insulin Market – Competitive Landscape
- 4.1. Company Market Share, 2015 (Subject To Data Availability)
- 4.2. Strategic Development
- 4.2.1. Acquisitions & Mergers
- 4.2.2. New Type Launch
- 4.2.3. Agreements, Partnerships, Collaborations And Joint Ventures
- 4.2.4. Research And Development, Product And Regional Expansion
- 4.3. Product Portfolio
- 4.4. Patent Analysis (2011-2016)
- 4.4.1. Patent Trend
- 4.4.2. Patent Share By Company
- 4.4.3. By Region
- Chapter 5. Global Human Insulin Market – Product Segment Analysis
- 5.1. Global Human Insulin Market: Product Segment Overview
- 5.1.1. Global Human Insulin Market Revenue Share, By Product Segment, 2015 And 2021
- 5.2. Drug
- 5.2.1. Global Human Insulin Market For Drug , 2015 – 2021 (USD Billion)
- 5.2.2. Insulin Analogs and Biosimilars
- 5.2.2.1. Global Human Insulin Market For Insulin Analogs and Biosimilars, 2015 – 2021 (USD Billion)
- 5.2.3. Human Insulin Biologics
- 5.2.3.1. Global Human Insulin Market For Human Insulin Biologics, 2015 – 2021 (USD Billion)
- 5.3. Drug Delivery Devices
- 5.3.1. Global Human Insulin Market For Drug Delivery Devices, 2015 – 2021 (USD Billion)
- 5.3.2. Pens
- 5.3.2.1. Global Human Insulin Market For Pens, 2015 – 2021 (USD Billion)
- 5.3.3. Pen Needles
- 5.3.3.1. Global Human Insulin Market For Pen Needles, 2015 – 2021 (USD Billion)
- 5.3.4. Syringes
- 5.3.4.1. Global Human Insulin Market For Syringes, 2015 – 2021 (USD Billion)
- 5.1. Global Human Insulin Market: Product Segment Overview
- Chapter 6. Global Human Insulin Market – Application Segment Analysis
- 6.1. Global Human Insulin Market: Application Segment Overview
- 6.1.1. Global Human Insulin Market Revenue Share, By Application Segment, 2015 And 2021
- 6.2. Insulin Dependent Diabetes Mellitus (Type 1)
- 6.2.1. Global Human Insulin Market For Insulin Dependent Diabetes Mellitus, 2015 – 2021 (USD Billion)
- 6.3. Non-Insulin Dependent Diabetes Mellitus (Type 2)
- 6.3.1. Global Human Insulin Market For Non-Insulin Dependent Diabetes Mellitus, 2015 – 2021 (USD Billion)
- 6.1. Global Human Insulin Market: Application Segment Overview
- Chapter 7. Global Human Insulin Market – Regional Segment Analysis
- 7.1. Global Human Insulin Market: Regional Overview
- 7.1.1. Global Human Insulin Market Revenue Share, By Region, 2015 And 2021
- 7.1.2. Global Human Insulin Market Revenue Share, By Application, 2015 And 2021
- 7.2. North America
- 7.2.1. North America Human Insulin Market Revenue, By Product, 2015 – 2021 , (USD Billion)
- 7.2.2. North America Human Insulin Market Revenue, By Application, 2015 – 2021 , (USD Billion)
- 7.3. Europe
- 7.3.1. Europe Human Insulin Market Revenue, By Product, 2015 – 2021 (USD Billion)
- 7.3.2. North America Human Insulin Market Revenue, By Application, 2015 – 2021 , (USD Billion)
- 7.4. Asia Pacific
- 7.4.1. Asia Pacific Human Insulin Market Revenue, By Product, 2015 – 2021 (USD Billion)
- 7.4.2. North America Human Insulin Market Revenue, By Application, 2015 – 2021 , (USD Billion)
- 7.5. Latin America
- 7.5.1. Latin America Human Insulin Market Revenue, By Product, 2015 – 2021 (USD Billion)
- 7.5.2. North America Human Insulin Market Revenue, By Application, 2015 – 2021 , (USD Billion)
- 7.6. Middle East And Africa
- 7.6.1. Middle East And Africa Human Insulin Market Revenue, By Product, 2015 – 2021 (USD Billion)
- 7.6.2. North America Human Insulin Market Revenue, By Application, 2015 – 2021 , (USD Billion)
- 7.1. Global Human Insulin Market: Regional Overview
- Chapter 8. Company Profile
- 8.1. Eli Lilly
- 8.1.1. Overview
- 8.1.2. Financials
- 8.1.3. Type Portfolio
- 8.1.4. Business Strategy
- 8.1.5. Recent Developments
- 8.2. GlaxoSmithCline
- 8.2.1. Overview
- 8.2.2. Financials
- 8.2.3. Type Portfolio
- 8.2.4. Business Strategy
- 8.2.5. Recent Developments
- 8.3. Biocon
- 8.3.1. Overview
- 8.3.2. Financials
- 8.3.3. Type Portfolio
- 8.3.4. Business Strategy
- 8.3.5. Recent Developments
- 8.4. Sanofi Aventis
- 8.4.1. Overview
- 8.4.2. Financials
- 8.4.3. Type Portfolio
- 8.4.4. Business Strategy
- 8.4.5. Recent Developments
- 8.5. Julphar
- 8.5.1. Overview
- 8.5.2. Financials
- 8.5.3. Type Portfolio
- 8.5.4. Business Strategy
- 8.5.5. Recent Developments
- 8.6. Novo Nordisk
- 8.6.1. Overview
- 8.6.2. Financials
- 8.6.3. Type Portfolio
- 8.6.4. Business Strategy
- 8.6.5. Recent Developments
- 8.7. SemBioSys
- 8.7.1. Overview
- 8.7.2. Financials
- 8.7.3. Type Portfolio
- 8.7.4. Business Strategy
- 8.7.5. Recent Developments
- 8.8. Wockhardt
- 8.8.1. Overview
- 8.8.2. Financials
- 8.8.3. Type Portfolio
- 8.8.4. Business Strategy
- 8.8.5. Recent Developments
- 8.1. Eli Lilly
- Chapter 9. Patents
- 9.1. U.S. (US Patents)
- 9.2. Europe (EP documents)
- 9.3. Japan (Abstracts of Japan)
- 9.4. Global (WIPO (PCT))
Similar Reports
Medical implants are permanent devices such as pacemakers or temporary devices such as fracture plates which are removed once their function is completed. These implants are made up of bone, tissue, skin, ceramics, metals, plastics, and other natural materials...
- Publish Date: August 21, 2016
- $5370
Ostomy is a surgery wherein an artificial opening, known as stoma, is created from the colon in the human body to eliminate body wastes such as urine, mucus, and stools, which are collected in artificial bags called ostomy drainage bags. These plastic/rub...
- Publish Date: December 1, 2016
- $5370
Laparoscopy is a minimally invasive procedure used to examine organs inside the abdomen or pelvic cavities by inserting a laparoscope through a small incision in the abdomen. A laparoscope comprises a long, thin tube with high-intensity light, and high-re...
- Publish Date: April 24, 2017
- $5370
